Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.61 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.61 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.61 |
| ▸ | F2 | P00734 | 4/20 | 0.56 |
| ▸ | CALCR | P30988 | 4/20 | 0.55 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.54 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.54 |
| ▸ | NPY1R | P25929 | 2/20 | 0.53 |
| ▸ | NPY2R | P49146 | 1/20 | 0.53 |
| ▸ | NPY4R | P50391 | 1/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31679466 | 0.86 | MAPK8 (0.57) | MAPK8MAPK9MAPK10F2CALCR | |
| SCHEMBL30132230 | 0.86 | OPRD1 (0.70) | F2NPY1R | |
| SCHEMBL30431820 | 0.85 | CALCR (0.60) | MAPK8MAPK9MAPK10F2CALCR | |
| SCHEMBL30176506 | 0.85 | NPY2R (0.63) | MAPK8MAPK9MAPK10F2CALCR | |
| SCHEMBL31182878 | 0.84 | CALCR (0.70) | CALCRNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL29822061 | 0.84 | KEAP1 (0.54) | F2CALCRKEAP1NPY1RNPY2R | |
| SCHEMBL30607405 | 0.84 | NPY2R (0.60) | MAPK8MAPK9MAPK10F2CALCR | |
| SCHEMBL30567780 | 0.84 | F2 (0.60) | MAPK8MAPK9MAPK10F2CALCR | |
| SCHEMBL30605188 | 0.83 | KEAP1 (0.60) | MAPK8MAPK9MAPK10F2CALCR | |
| SCHEMBL30576916 | 0.83 | NPY2R (0.55) | MAPK8MAPK9MAPK10CALCRNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240325487-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2024-10-03 | — | — | US | disclosed |
| US-11813304-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| CN-114404588-A | Compounds and methods for inhibiting phosphate transport | 阿德利克斯公司 | 2022-04-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325487-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | MAPK8 1993/4885MAPK9 1293/4885MAPK10 1883/4885 |
| US-11813304-B2 | Compounds and methods for inhibiting phosphate transport | SLC34A3, SLC34A2, SLC34A1 | MAPK8 1993/4885MAPK9 1293/4885MAPK10 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.